Adaptive radiotherapy for pelvic cancers
Official title: Pelvis Adaptive Radiation Therapy
Run by Royal North Shore Hospital · NCT06650033 · Data updated 2026-11-12
This trial will test whether radiation therapist–led adaptive radiotherapy, including smaller treatment margins, can reduce side effects for adults getting curative or adjuvant pelvic radiotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 280 (estimated) |
| Sponsor | Royal North Shore Hospital Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (St Leonards, New South Wales) |
| Status | Recruiting |
| Started | October 9, 2025 |
| Main results expected | November 30, 2029 |
| Study ends | November 30, 2031 |
| Registry record updated | February 5, 2026 |
| Trial ID | NCT06650033 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with pelvic cancers—including prostate requiring nodal treatment or post-prostatectomy, bladder, rectal, anal, adjuvant gynaecological cases, or pelvic nodal disease—who are receiving curative or adjuvant pelvic radiotherapy, have ECOG 0–2, can consent, and meet imaging size limits are ideal candidates.
✕Probably not a fit
Patients with hip prostheses, a patient-to-skin separation >24 cm on imaging, those receiving only palliative pelvic radiotherapy, or those unable to tolerate the adaptive workflow are unlikely to qualify or benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a two‑phase program using daily adaptive radiotherapy (ART) that accounts for day-to-day anatomical changes during pelvic radiation. In phase 1 the study will test the safety and feasibility of a radiation therapist–led ART workflow; if safe, phase 2 will randomize patients to ART with reduced planning margins versus standard image-guided radiotherapy. The interventions use image guidance and on‑table adaptation to update target contours and potentially shrink CTV/PTV margins. The project is being run at Royal North Shore Hospital with prior local RT advanced-practitioner training informing the workflow.
Why it matters
Potential benefit: If successful, this approach could safely reduce radiation-related side effects by allowing smaller treatment margins and improving patients' quality of life.
How similar studies have gone: Prior ART studies have shown promising reductions in acute toxicity, but widespread uptake is limited and RT-led daily adaptive workflows are less well tested, making this approach relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \> 18 2. ECOG performance status 0-2 3. Patients receiving curative or adjuvant pelvic radiation including: 1. Prostate cancer where nodal treatment is required 2. Prostate cancer post prostatectomy 3. Bladder cancer 4. Rectal cancer 5. Anal cancer 6. Adjuvant radiotherapy for gynaecological cancers 7. Pelvic Lymph nodes only 4. Ability to understand and the willingness to sign an informed consent Exclusion Criteria: * Hip prosthesis * Patient separation from approximate radiation centre to skin edge \> 24cm, measured on diagnostic scan
Where it's running
-
Northern Sydney Local Health District
St Leonards, New South Wales, Australia Recruiting
Study contacts
- Principal investigator: Andrew Kneebone — Northern Sydney Local Health District
- Study coordinator: Nada Cheikh-Ali
- Email: nada.cheikhali@health.nsw.gov.au
- Phone: +61294631345
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PSMA PET/CT for GBM patients on bevacizumab
This study tests PSMA PET/CT scans in adults with IDH-wildtype glioblastoma who are receiving bevacizumab to see how PSMA expression relates to VEGF in their tumors.
-
Adaptive radiation for prostate cancer
This study tests whether daily adaptive radiotherapy led by radiation therapists, with the option to use smaller treatment margins, can reduce side effects for men having prostate radiotherapy.
-
AI-assisted contouring for breast cancer radiation treatment
This study is testing if using AI to help outline areas for radiation treatment in breast cancer patients is just as good and faster than having doctors do it by hand.
-
3D printed applicators for treating gynecologic cancers
This study is testing whether 3D-printed custom applicators can make radiation treatment more effective for patients with gynecologic cancers.
-
Lower-dose radiation for non-hypoxic HPV-positive oropharyngeal cancer guided by FMISO PET
This trial tests whether people with HPV-positive oropharyngeal cancer who show no tumor hypoxia on FMISO PET can be treated safely with a much lower total radiation dose.
-
Using Esketamine to Treat Depression in Real-world Settings
This study is testing if adding a nasal spray called Esketamine to regular antidepressant treatment can help people with Major Depressive Disorder feel better in real-life settings.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.